Indirect treatment comparisons and biologics

J Allergy Clin Immunol. 2019 Jan;143(1):84-86. doi: 10.1016/j.jaci.2018.11.005.

Authors

David Mauger¹, Andrea J Apter²

Affiliations

¹ Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pa.
² Division of Pulmonary, Allergy Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa. Electronic address: andrea.apter@uphs.upenn.edu.

PMID: 30612667
DOI: 10.1016/j.jaci.2018.11.005

No abstract available

Keywords: Asthma; benralizumab; biologic; monoclonal antibody; reslizumab; systematic analysis.

Publication types

Editorial
Comment

MeSH terms

Anti-Asthmatic Agents*
Asthma*
Biological Products*
Eosinophils
Humans
Interleukin-5

Substances

Anti-Asthmatic Agents
Biological Products
Interleukin-5